Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 13
2003 18
2004 10
2005 22
2006 32
2007 26
2008 25
2009 42
2010 40
2011 31
2012 27
2013 34
2014 39
2015 44
2016 44
2017 44
2018 43
2019 50
2020 41
2021 39
2022 40
2023 36
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

652 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB, Kido A. Yang BB, et al. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. ...After repe …
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases i …
Pegfilgrastim.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012. Drugs. 2002. PMID: 12010086 Review.
Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count increases. ...Moreover, the mean duration of grade 4 neutropenia in cycles 2 to 4 of chemotherapy was significantly lower in recipients of pegfilgrastim th …
Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count increases. ...Moreover …
LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. BioDrugs. 2019. PMID: 30887256 Review.
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to be approved in the EU. ...The role of reference pegfilgrastim in the management of chemotherapy-induced neutropenia is well establishe …
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to b …
Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C, Lewis S, Sandschafer D, Crawford J. De Oliveira Brandao C, et al. Curr Med Res Opin. 2023 May;39(5):707-718. doi: 10.1080/03007995.2023.2196197. Epub 2023 Apr 8. Curr Med Res Opin. 2023. PMID: 36976784 Review.
Nine million patients have received pegfilgrastim since its approval in early 2002. The pegfilgrastim on-body injector (OBI) is an innovative device facilitating the time-released auto-injection of pegfilgrastim approximately 27 h after chemotherapy, as clini …
Nine million patients have received pegfilgrastim since its approval in early 2002. The pegfilgrastim on-body injector (OBI) i …
Pegfilgrastim.
Willis F, Pettengell R. Willis F, et al. Expert Opin Biol Ther. 2002 Dec;2(8):985-92. doi: 10.1517/14712598.2.8.985. Expert Opin Biol Ther. 2002. PMID: 12517276 Review.
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy induced neutropenia. Pegfilgrastim provides clinical and quality of life benefits for patients as a result of its once per cycle admini …
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy in …
Pharmacokinetics of pegfilgrastim.
Zamboni WC. Zamboni WC. Pharmacotherapy. 2003 Aug;23(8 Pt 2):9S-14S. doi: 10.1592/phco.23.9.9s.32888. Pharmacotherapy. 2003. PMID: 12921217 Review.
Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) with a long half-life and sustained duration of action. ...Preclinical animal data have shown that the clearance of pegfilgrastim depends on dosage and absolute neutrophil count, with pegfilgrastim …
Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) with a long half-life and sustained duration of action. ...Preclinic …
Pegfilgrastim-induced hyperleukocytosis.
Snyder RL, Stringham DJ. Snyder RL, et al. Ann Pharmacother. 2007 Sep;41(9):1524-30. doi: 10.1345/aph.1K093. Epub 2007 Jul 31. Ann Pharmacother. 2007. PMID: 17666580
No sequelae from this adverse effect occurred. DISCUSSION: Pegfilgrastim has unique saturable neutrophil receptor-mediated clearance, the ability for self-regulation. ...The pegfilgrastim dose in children is under investigation; however, 100-110 microg/kg has …
No sequelae from this adverse effect occurred. DISCUSSION: Pegfilgrastim has unique saturable neutrophil receptor-mediated cle …
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, Okusaka T, Furuse J. Ozaka M, et al. Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023. doi: 10.1007/s00280-018-3577-9. Epub 2018 Apr 9. Cancer Chemother Pharmacol. 2018. PMID: 29633005 Clinical Trial.
The incidence of grade 3 or higher neutropenia was 47.8%. Serious adverse events occurred in six patients (8.7%). All AE proportions were less than those in the previous Japanese full-dose phase II study. ...Modified FOLFIRINOX in this study has an improved safety p …
The incidence of grade 3 or higher neutropenia was 47.8%. Serious adverse events occurred in six patients (8.7%). All AE propo …
Pegfilgrastim-induced large vessel vasculitis.
Saito H, Suda T, Oishi N, Matsushita E. Saito H, et al. BMJ Case Rep. 2021 Jun 2;14(6):e243757. doi: 10.1136/bcr-2021-243757. BMJ Case Rep. 2021. PMID: 34083201 Free PMC article. No abstract available.
First Pegfilgrastim Biosimilar Approved.
Aschenbrenner DS. Aschenbrenner DS. Am J Nurs. 2018 Oct;118(10):19-20. doi: 10.1097/01.NAJ.0000546389.75712.6e. Am J Nurs. 2018. PMID: 30260881 No abstract available.
652 results